Drug intelligence / Profile preview

ERI-2206

Development stage: Preclinical
Lead developer: Tempest Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

ERI-2206 is a preclinical CAR T-cell therapy program that was acquired by Tempest Therapeutics from Erigen and Factor Bioscience. This acquisition was part of a strategic move by Tempest to expand its pipeline into cell therapies, adding three preclinical assets, including ERI-2206.

Beyond the preview

Go deeper on ERI-2206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERI-2206.

Explore the full profile